

**Male Chlamydia Screening Consultation  
Atlanta, Georgia  
March 28 – 29, 2006**

**Meeting Report  
May 22, 2007**

**Division of STD Prevention  
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention  
U.S. Centers for Disease Control and Prevention**

## Male Chlamydia Screening Consultation, March 28-29, 2006

### Meeting Report

This report summarizes a Centers for Disease Control and Prevention (CDC) meeting held March 28-29, 2006 on male chlamydia screening. CDC convened this meeting to review evidence and make recommendations to programs that were currently screening, or planning to screen men for *Chlamydia trachomatis* infection (Ct). Consultants reviewed surveillance data on Ct in men; the literature on effectiveness, acceptability, behavioral and demographic characteristics that could be used to target screening; cost-effectiveness; partner management; and the relative performance of nucleic acid amplification tests (NAATs) and the leukocyte esterase test (LET). Working groups examined published evidence in these specific subject areas and compiled summary reports, rating the quality and strength of the evidence for various recommendations. The assembled consultants provided strength of support for these recommendations, which are included in this summary. A list of participants is provided in Appendix A.

This report provides background and purpose of the meeting, the meeting process, and a summary of key recommendations based on available scientific data.

#### **I. Background, Purpose, and Process**

The purpose of the meeting was to use available scientific literature to develop guidance on male screening for Ct for programs currently screening, or planning to implement screening. The intent of the meeting was not to provide evidence for or against screening men for Ct, and the consultants also did not address the question of whether programs should expand existing screening or not. Future evaluations, including modeling data, will help address the relative value of screening men for Ct.

Seven topics were selected for presentation: 1) a review of venues and Ct prevalence; 2) a review of prevalence of Ct among men in the U.S.; 3) a review of behavioral and demographic features associated with Ct among men; 4) cost-effectiveness issues; 5) laboratory issues; 6) partner management; and 7) re-infection. After the presentations, workgroups met to discuss guidance generated from the review of data, and quality and strength of the evidence. A summary presentation from each workgroup generated the recommendations. The expert consultants developed a level of support for each recommendation, using a five-point scale.

## II. Introduction to Recommendations

The consultants were in agreement that programs that screen males for Ct should include education on Ct, and that a primary focus of programs should remain on screening women, as the most significant health burdens caused by Ct, such as pelvic inflammatory disease and its sequelae of chronic pelvic pain, ectopic pregnancy, and infertility, occur in women. The following recommendations were considered the most important focus for screening men for Ct. The average score is the simple average of the scores given by each consultant to each recommendation that emerged from the workgroups. Quality of evidence and strength of recommendation were rated by the workgroups according to the scales used by the U.S. Preventive Services Task Force (USPSTF)(1). However, the USPSTF has not assessed these recommendations. Below is a table listing all recommendations which had an average score of 4.0 or higher.

### Recommendations for programs that are currently screening men, or planning to screening men for Ct infection in order to select appropriate populations to screen

Recommendation	Average Score (Median) 1-5 (5 is strongest)	Quality of the Evidence *	Strength of the Recommendation †	References
Urine is the specimen of choice and NAATs are the test of choice for screening men for Ct	5.00 (5)	I	A	(2-4)
LET is not recommended for screening males for Ct	5.00 (5)	I	A	(5;6)
Males attending STD clinics should be screened for Ct (including screening asymptomatic men and testing men with symptoms) <sup>‡,§</sup>	4.87 (5)	II	A	(7) <sup>‡‡</sup> (8)
Screen men attending National Job Training Program	4.84 (5)	I/II	A	(9;10) <sup>‡‡</sup>
Pooling of urine specimens does not diminish NAAT performance and may be considered a cost saving methodology at certain prevalence levels <sup>  </sup>	4.76 (5)	I	A	(11-13)

<b>Recommendation</b>	<b>Average Score (Median) 1-5 (5 is strongest)</b>	<b>Quality of the Evidence*</b>	<b>Strength of the Recommendation†</b>	<b>References</b>
Screen all males in military <30 years of age with any lifetime sexual experience	4.66 (5)	I	A	(14;15)
Males <30 years of age entering jails should be screened for Ct <sup>§,¶</sup>	4.59 (5)	I/II	A	(9;16) <sup>‡‡</sup>
Partners of men with Ct should be referred for treatment and management of Ct <sup>**</sup>	4.46 (5)	I	A	(17)
There is increasing evidence that expedited partner therapy works well for partners of men with Ct <sup>**</sup>	4.46 (5)	II	A	(17)
Males with Ct infection should be re-screened at 3 months for repeat Ct	4.42 (5)	II	A	(18;19)
Males entering juvenile facilities should be screened for Ct <sup>§,††</sup>	4.39 (5)	II	B	(9) <sup>‡‡</sup>
In communities with high Ct prevalences (either sex), programs should consider screening men in EDs (<25), attending HS clinics, and attending adolescent clinics <sup>§§</sup>	4.18 (4)	II / III	B / C	(20) <sup>‡‡</sup> (16;21-23)

Notes:

Abbreviations: Ct = chlamydia, ED = emergency department, EPT = expedited partner therapy, HS = high school, LET = leukocyte esterase test, NAAT = nucleic acid amplification test, STD = sexually transmitted disease

\* I = Good, II = Fair, III = poor; see Appendix B. (1)

† A = strongly recommended, B = recommended, C = no recommendation for or against, D = recommended against, I = insufficient evidence; see Appendix B. (1)

‡ Consultants also considered a more restrictive recommendation to screen in STD clinics all males < 30 years of age with any lifetime sexual experience. Average (median) score was 4.78 (5).

§ Consultants did not consider regional variation in prevalence and noted that in some areas local prevalence may impact the strength of this recommendation.

|| Consultants noted that nomograms have been developed that indicate what number of specimens are appropriate to pool at a given prevalence. (11)

¶ Consultants also considered a recommendation to screen in jails all males with any lifetime sexual experience. Average (median) score was 4.48 (5).

\*\* Consultants considered these recommendations together.

†† Consultants considered prevalence cutoffs of 2% - 4%, and considered a blanket recommendation to screen regardless of prevalence, but were not able to reach a consensus on a particular cutoff.

‡‡ Consultants reviewed the unpublished data from this source.

§§ There was less agreement and weak support for screening in these venues in communities without high prevalence.

Other recommendations for which there was limited support included screening men <30 in a variety of other venues, such as primary care, family court, street outreach, schools, and some community based organization (CBO) settings. There was no consensus on the state of the cost-effectiveness literature because of differences among studies regarding methodology and a lack of empiric evidence of the impact of screening men on the prevalence in women.

### **III. Conclusions/Caveats**

The consultants agreed that screening men for Ct infection presents challenges to programs including limited resources, lack of knowledge of high prevalence settings, and lack of information on the impact of screening men for Ct on rates and outcomes in women. A premise of the consultation was that STD programs should screen women less than 26 years of age for chlamydia infection as a primary focus (24;25) and that screening men for Ct should be considered as a secondary focus to prevent Ct infection and sequelae among women.

**Meeting Report prepared by:**

Eileen Dunne, MD  
Centers for Disease Control and Prevention, Atlanta, Georgia

Dennis V. Ferrero, MPH  
University of the Pacific, Stockton, California

David N. Fisman, MD, MPH, FRCP (C)  
Child Health Evaluative Sciences Research Institute of the Hospital for Sick Children, Toronto, Ontario, Canada

Dennis Fortenberry, MD, MPH  
Indiana University School of Medicine, Indianapolis, Indiana

Charlotte A. Gaydos, DrPH  
Johns Hopkins University, Baltimore, Maryland

William M. Geisler, MD, MPH  
University of Alabama at Birmingham, Birmingham, Alabama

Thomas L. Gift, PhD  
Centers for Disease Control and Prevention, Atlanta, Georgia

Martin Goldberg  
Philadelphia Department of Public Health, Philadelphia, Pennsylvania

Matthew Hogben, PhD  
Centers for Disease Control and Prevention, Atlanta, Georgia

Charlotte Kent, PhD, MPH  
San Francisco Department of Public Health, San Francisco, California

Jeanne M. Marrazzo, MD, MPH,  
University of Washington School of Medicine, Seattle, Washington

Donald Orr, MD  
Indiana University-Purdue University, Indianapolis, Indiana

John R. Papp, PhD  
Centers for Disease Control and Prevention, Atlanta, Georgia

Cornelis A. Rietmeijer, MD, PhD  
Denver Public Health, Denver, Colorado

Catherine L. Satterwhite, MPH, MSPH  
Centers for Disease Control and Prevention, Atlanta, Georgia

## Appendix A: List of Consultants and Organizations

<b>Consultants and Organizations List for Male Chlamydia Screening Consultation (Alphabetical by Name)</b>	
<b>Name</b>	<b>Affiliation</b>
Bauer, Heidi, MD,MPH	California Department of Health Services, STD Control
Blackburn, Pat, MPH	Center for Health Training
Blake, Diane, MD	University of Massachusetts
Cohen, Deborah, MD, MPH	RAND Corporation
de Ravello, Lori, MPH	Indian Health Service
Ferrero, Dennis, MPH	University of the Pacific
Fisman, David, MD, MPH, FRCPC	Drexel University (visiting at Princeton)
Fortenberry, Dennis, MD MS	Indiana University School of Medicine
Gaydos, Charlotte, DrPH	Johns Hopkins University
Geisler, William, MD, MPH	University of Alabama-Birmingham
Goldberg, Martin, BS	Philadelphia Department of Public Health
Gunn, Robert, MD, MPH	STD Control, San Diego County Public Health Department
Hook III, Ned, MD, MPH	University of Alabama-Birmingham
Kent, Charlotte, PhD, MPH	San Francisco Department of Public Health
Kissinger, Patty, PhD	Tulane University
Lincoln, Tom, MD	Hampden County (MA) Correctional Center
Marrazzo, Jeanne, MD, MPH	University of Washington
Martin, David, MD	Louisiana State University Health Sciences Center-New
Miller, William, MD, PhD, MPH	University of North Carolina-Chapel Hill
Orr, Donald, MD	Indiana University-Purdue University Indianapolis
Potterat, John, BA	Colorado Springs Health Department (retired)
Rietmeijer, Kees, MD, PhD	Denver Public Health
Schachter, Julius, PhD	University of California-San Francisco
Schillinger, Julie, MD MSc	New York City Department of Health and Mental Hygiene
Shafer, Mary Ann, MD	University of California-San Francisco
Steece, Richard, PhD	National Infertility Prevention Project
<b>Organizational Representatives</b>	<b>Organization</b>
Burstein, Gale, MD, MPH	Society for Adolescent Medicine
Dimitrakov, Jordan, MD, PhD	American Urological Association and Harvard Medical
Hallerdin, Jule, MN, MPH, CNM	Office of Population Affairs
Meyers, David, MD	US Preventive Services Task Force
Moskosky, Susan, MS, RNC	Office of Population Affairs
Tan, Leitjan, MS, PhD	American Medical Association
Watson, Kathleen O'Connor, RN MS	National Coalition of STD Directors

<b>CDC Participants List for Male Chlamydia Screening Consultation (Alphabetical by Name)</b>	
<b>Name</b>	<b>Affiliation</b>
Aral, Sevgi, PhD	NCHHSTP*, DSTDP**
Ballard, Ronald, PhD	NCHHSTP, DSTDP
Berman, Stuart, MD, ScM	NCHHSTP, DSTDP
Chorba, Terry, MD, MPH, MPA	NCHHSTP
DeLisle, Susan, ARNP, MPH	NCHHSTP, DSTDP
Douglas, John, MD	NCHHSTP, DSTDP
Dunne, Eileen, MD, MPH	NCHHSTP, DSTDP
Gift, Thomas, PhD	NCHHSTP, DSTDP
Groseclose, Sam, DVM, MPH	NCHHSTP, DSTDP
Johnson, Robert, MD	NCHHSTP, DSTDP
Hogben, Matthew, PhD	NCHHSTP, DSTDP
Koumans, Emilia, MD, MPH	NCHHSTP, DSTDP
Kamb, Mary, MD, MPH	NCHHSTP, DSTDP
Kissin, Dmitry, MD	NCCDPHP#, DRH##
Kraft, Joan, PhD	NCCDPHP, DRH
Lehnerr, John, BA	NCCDPHP, DRH
Markowitz, Lauri, MD	NCHHSTP, DSTDP
Newhall, Jim, PhD	CDC, Office of Chief Science Officer
Papp, John, PhD	NCHHSTP, DSTDP
Peterman, Tom, MD, MSc	NCHHSTP, DSTDP
Pulver, Amy, MBA, MA	NCHHSTP, DSTDP
Satterwhite, Catherine Lindsey, MPH, MSPH	NCHHSTP, DSTDP
Seechuk, Kim, MPH	NCHHSTP, DSTDP
Shapiro, Steve, BS	NCHHSTP, DSTDP
Valdiserri, Ronald, MD, MPH	NCHHSTP
Warner, Lee, PhD, MPH	NCCDPHP, DRH
Walsh, Cathleen, DrPH	NCHHSTP, DSTDP
Weinstock, Hillard, MD, MPH	NCHHSTP, DSTDP
Xu, Fujie, MD, PhD	NCHHSTP, DSTDP

\* National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention

\*\* Division of STD Prevention

# National Center for Chronic Disease and Public Health Promotion

## Division of Reproductive Health



## Appendix B: US Preventive Services Task Force Standards (1)

### How the U.S. Preventive Services Task Force Grades Its Recommendations

The U.S. Preventive Services Task Force (USPSTF) grades its recommendations based on the strength of evidence and magnitude of net benefit (benefits minus harms).

**A.** The USPSTF strongly recommends that clinicians provide [the service] to eligible patients. *The USPSTF found good evidence that [the service] improves important health outcomes and concludes that benefits substantially outweigh harms.*

**B.** The USPSTF recommends that clinicians provide [the service] to eligible patients. *The USPSTF found at least fair evidence that [the service] improves important health outcomes and concludes that benefits outweigh harms.*

**C.** The USPSTF makes no recommendation for or against routine provision of [the service]. *The USPSTF found at least fair evidence that [the service] can improve health outcomes but concludes that the balance of benefits and harms is too close to justify a general recommendation.*

**D.** The USPSTF recommends against routinely providing [the service] to asymptomatic patients. *The USPSTF found at least fair evidence that [the service] is ineffective or that harms outweigh benefits.*

**I.** The USPSTF concludes that the evidence is insufficient to recommend for or against routinely providing [the service]. *Evidence that [the service] is effective is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.*

The USPSTF grades the quality of the overall evidence for a service on a 3-point scale (good, fair, poor).

**Good:** Evidence includes consistent results from well-designed, well-conducted studies in representative populations that directly assess effects on health outcomes.

**Fair:** Evidence is sufficient to determine effects on health outcomes, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence on health outcomes.

**Poor:** Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information on important health outcomes.

## References

- (1) US Preventive Services Task Force. The guide to clinical preventive services. 2006. Washington, Agency for Healthcare Research and Quality.
- (2) Johnson RE, Green TA, Schachter J et al. Evaluation of nucleic acid amplification tests as reference tests for *Chlamydia trachomatis* infections in asymptomatic men. *J Clin Microbiol* 2000; 38(12):4382-4386.
- (3) Chernesky MA, Martin DH, Hook EW, III et al. Ability of new APTIMA CT and APTIMA GC assays to detect *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in male urine and urethral swabs. *J Clin Microbiol* 2005; 43(1):127-131.
- (4) Marrazzo JM, White C, Krekeler B et al. Community-based urine screening for *Chlamydia trachomatis* with a ligase chain reaction assay. *Ann Int Med* 1997; 127:796-803.
- (5) Blake DR, Lemay CA, Gaydos CA, Quinn TC. Performance of urine leukocyte esterase in asymptomatic male youth: another look with nucleic acid amplification testing as the gold standard for chlamydia detection. *J Adolesc Health* 2005; 36(4):337-341.
- (6) Wood BJ, Gaydos JC, McKee KT, Jr., Gaydos CA. Usefulness of the urine leukocyte esterase test compared to nucleic acid amplification tests (NAATs) for screening non-healthcare-seeking males for *C. trachomatis* and *N. gonorrhoeae* infections. *Mil Med* 2007; In press.
- (7) Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2005 [Report]. 2006. Atlanta, GA, US Department of Health and Human Services.
- (8) Kohl KS, Sternberg MR, Markowitz LE et al. Screening of males for *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infections at STD clinics in three US cities--Indianapolis, New Orleans, Seattle. *Int J STD AIDS* 2004; 15(12):822-828.
- (9) Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2005 supplement-chlamydia prevalence monitoring project annual report, 2005. [Report] 2006. Atlanta, GA, US Department of Health and Human Services.
- (10) Joesoef MR, Mosure DJ. Prevalence of chlamydia in young men in the United States from newly implemented universal screening in a national job training program. *Sex Transm Dis* 2006; 33(6):636-639.
- (11) Kacena KA, Quinn SB, Hartman Suzanne C., Quinn TC, Gaydos CA. Pooling of urine samples for screening for *Neisseria gonorrhoeae* by ligase chain reaction: accuracy and application. *J Clin Microbiol* 1998; 36(12):3624-3628.
- (12) Peeling RW, Toye B, Jessamine P, Gemmill I. Pooling of urine specimens for PCR testing: a cost saving strategy for *Chlamydia trachomatis* control programmes. *Sex Transm Infect* 1998; 74:66-70.

- (13) Morre SA, Meijer CJLM, Munk C et al. Pooling of urine specimens for detection of asymptomatic *Chlamydia trachomatis* infections by PCR in a low-prevalence population: cost-saving strategy for epidemiological studies and screening programs. *J Clin Microbiol* 2000; 38(4):1679-1680.
- (14) Cecil JA, Howell MR, Tawes JJ et al. Features of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infection in male army recruits. *J Infect Dis* 2001; 184:1216-1219.
- (15) Arcari CM, Gaydos JC, Howell MR, McKee KT, Jr., Gaydos CA. Feasibility and short-term impact of linked education and urine screening interventions for chlamydia and gonorrhea in male army recruits. *Sex Transm Dis* 2004; 31(7):443-447.
- (16) Schillinger JA, Dunne EF, Chapin JB et al. Prevalence of *Chlamydia trachomatis* infection among men screened in 4 U.S. cities. *Sex Transm Dis* 2005; 32(2):74-77.
- (17) Centers for Disease Control and Prevention. Expedited partner therapy in the management of sexually transmitted diseases. [Report] 2006. Atlanta, GA, US Department of Health & Human Services.
- (18) Fung M, Scott KC, Kent CK, Klausner JD. Chlamydia and gonorrhea re-infection among males: a systematic review of data to evaluate the need for re-testing. *Sex Transm Infect* 2007; in press.
- (19) Dunne EF, Schillinger JA, Chapin JB et al. Reinfection with *Chlamydia trachomatis*: rate and predictors of reinfection among males. [Abstract] ISSTD Congress, Ottawa, Canada 2003. Abstract #409.
- (20) Asbel LE, Newbern EC, Salmon M, Spain CV, Goldberg M. School-based screening for *Chlamydia trachomatis* and *Neisseria gonorrhoeae* among Philadelphia public high school students. *Sex Transm Dis* 2006; 33(10):614-620.
- (21) Todd CS, Haase C, Stoner BP. Emergency department screening for asymptomatic sexually transmitted infections. *Am J Public Health* 2001; 91(3):461-464.
- (22) Mehta SD, Rothman RE, Kelen GD, Quinn TC, Zenilman JM. Unsuspected gonorrhea and chlamydia in patients of an urban adult emergency department. *Sex Transm Dis* 2001; 28(1):33-39.
- (23) Cohen DA, Nsuami M, Martin DH, Farley TA. Repeated school-based screening for sexually transmitted diseases: a feasible strategy for reaching adolescents. *Pediatrics* 1999; 104(6):1281-1285.
- (24) US Preventive Services Task Force. Screening for chlamydial infection: recommendations and rationale. *Am J Prev Med* 2001; 20(3 Suppl):90-94.
- (25) Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2006. *MMWR* 2006; 55(RR-11):1-94.